Zydus Pharmaceu Patent-Cliff Exposure & CMS Drug Spending Portfolio

Zydus Pharmaceu (US): 10 reconciled FDA prescription therapies, $213.0M 2024 CMS Part D & Medicaid spend, and $9,504 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies10
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$213.0M
2024 Medicare Part D Spend$174.8M
2024 Medicaid Spend$38.3M
California HCAI SB 17 FilingsSpecialty launch notice ($9,504 intro WAC)